Sumitomo Pharma Co., Ltd.
DNPUF
Price:
$3.8
Market Cap:
$233.60B
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In additio...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2012-01-17
Stock Exchange
PNK
Ticker
DNPUF
PE Ratio
[-0.84]
ROE
[-97.03%]
Current Ratio
[0.65]
Dividend Yield
[0%]
Enterprise Value
[545.27B]
Dividend History
The ROE as of November 2024 (TTM) for Sumitomo Pharma Co., Ltd. (DNPUF) is -97.03%
According to Sumitomo Pharma Co., Ltd.’s latest financial reports and current stock price. The company's current ROE is -97.03%. This represents a change of 181.17% compared to the average of -34.51% of the last 4 quarters.
Sumitomo Pharma Co., Ltd. (DNPUF) Historical ROE (quarterly & annually)
How has DNPUF ROE performed in the past?
The mean historical ROE of Sumitomo Pharma Co., Ltd. over the last ten years is -15.62%. The current -97.03% ROE has changed 521.38% with respect to the historical average. Over the past ten years (40 quarters), DNPUF's ROE was at its highest in in the June 2024 quarter at 9.91%. The ROE was at its lowest in in the March 2024 quarter at -126.40%.
Average
-15.62%
Median
7.25%
Minimum
-201.82%
Maximum
11.81%
Sumitomo Pharma Co., Ltd. (DNPUF) ROE by Quarter and Year
Discovering the peaks and valleys of Sumitomo Pharma Co., Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.00%
Maximum Annual ROE = 11.81%
Minimum Annual Increase = -297.40%
Minimum Annual ROE = -201.82%
| Year | ROE | Change |
|---|---|---|
| 2024 | -201.82% | 1.00% |
| 2023 | -18.32% | -297.40% |
| 2022 | 9.28% | -4.16% |
| 2021 | 9.68% | 25.81% |
| 2020 | 7.70% | -21.15% |
| 2019 | 9.76% | -17.31% |
| 2018 | 11.81% | 73.66% |
| 2017 | 6.80% | 22.90% |
| 2016 | 5.53% | 61.51% |
| 2015 | 3.42% | -31.96% |
Sumitomo Pharma Co., Ltd. (DNPUF) Average ROE
How has DNPUF ROE performed in the past?
The current ROE of Sumitomo Pharma Co., Ltd. (DNPUF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-70.29%
5-year avg
-38.70%
10-year avg
-15.62%
Sumitomo Pharma Co., Ltd. (DNPUF) ROE vs. Peers
How is DNPUF’s ROE compared to its peers?
Sumitomo Pharma Co., Ltd.’s ROE is less than Hypera S.A. (13.22%), less than Indivior PLC (4.23%), less than YourWay Cannabis Brands Inc. (0%), greater than Cumberland Pharmaceuticals Inc. (-40.17%), less than RAMM Pharma Corp. (0%), less than Genomma Lab Internacional, S.A.B. de C.V. (2.60%), greater than Speakeasy Cannabis Club Ltd. (-16.76%), less than City View Green Holdings Inc. (65.45%), greater than Craftport Cannabis Corp. (-194.22%), greater than Orexo AB (publ) (-359.08%), less than Indivior PLC (4.23%), greater than C21 Investments Inc. (-14.98%), greater than RavenQuest BioMed Inc. (-203.42%), less than Bhang Inc. (400.77%), greater than Willow Biosciences Inc. (-325.63%), greater than Alpha Teknova, Inc. (-37.32%), less than Guardion Health Sciences, Inc. (77.24%), less than Lifecore Biomedical, Inc. (17.23%), greater than Organogenesis Holdings Inc. (-2.69%), greater than Petros Pharmaceuticals, Inc. (-76.66%),
| Company | ROE | Market cap |
|---|---|---|
| 13.22% | $2.17B | |
| 4.23% | $2.89B | |
| 0% | $17.82M | |
| -40.17% | $14.88M | |
| 0% | $15.16M | |
| 2.60% | $1.30B | |
| -16.76% | $1.31K | |
| 65.45% | $3.75M | |
| -194.22% | $6.46B | |
| -359.08% | $37.21M | |
| 4.23% | $3.01B | |
| -14.98% | $23.17M | |
| -203.42% | $482.11K | |
| 400.77% | $23.48K | |
| -325.63% | $8.08M | |
| -37.32% | $390.75M | |
| 77.24% | $4.35M | |
| 17.23% | $269.21M | |
| -2.69% | $536.94M | |
| -76.66% | $2.70M |
Build a custom stock screener for Sumitomo Pharma Co., Ltd. (DNPUF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Sumitomo Pharma Co., Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Sumitomo Pharma Co., Ltd. (DNPUF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Sumitomo Pharma Co., Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Sumitomo Pharma Co., Ltd.'s ROE?
How is the ROE calculated for Sumitomo Pharma Co., Ltd. (DNPUF)?
What is the highest ROE for Sumitomo Pharma Co., Ltd. (DNPUF)?
What is the 3-year average ROE for Sumitomo Pharma Co., Ltd. (DNPUF)?
What is the 5-year average ROE for Sumitomo Pharma Co., Ltd. (DNPUF)?
How does the current ROE for Sumitomo Pharma Co., Ltd. (DNPUF) compare to its historical average?